KMT2A and acute lymphoblastic leukemia: Moreover, long‐term pretreatment with low‐dose decitabine moderately sensitizes MLL‐rearranged ALL cells toward conventional chemotherapeutics as well as toward known epigenetic‐based compounds and anti‐neoplastic agents, in vitro.